(Q44383427)

English

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

scientific article published on 30 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

0 references

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme (English)

1 reference

Europe PubMed Central

2 December 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

B Zinman

1

1 reference

Europe PubMed Central

2 December 2017

W E Schmidt

2

1 reference

Europe PubMed Central

2 December 2017

A Moses

3

1 reference

Europe PubMed Central

2 December 2017

N Lund

4

1 reference

Europe PubMed Central

2 December 2017

S Gough

5

1 reference

Europe PubMed Central

2 December 2017

publication date

30 October 2011

1 reference

Europe PubMed Central

2 December 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

2 December 2017

14

1 reference

Europe PubMed Central

2 December 2017

77-82

1 reference

Europe PubMed Central

2 December 2017

1

1 reference

Europe PubMed Central

2 December 2017

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01493.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01493.X

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44383427&oldid=2020746417"